XNCR Xencor Inc
- Stocks
- Healthcare
- NASDAQ: XNCR
Price (delayed)
$9.24
Market cap
$657.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.05
Enterprise value
$839.86M
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in
Highlights
Xencor's debt has decreased by 13% YoY and by 4.2% QoQ
The company's net income fell by 42% YoY but it rose by 11% QoQ
The EPS has decreased by 27% YoY but it has increased by 15% QoQ
XNCR's quick ratio is down by 27% year-on-year and by 10% since the previous quarter
Key stats
What are the main financial stats of XNCR
Market
Valuations
Earnings
Shares outstanding
71.17M
Market cap
$657.62M
Enterprise value
$839.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.02
Price to sales (P/S)
5.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.6
Revenue
$127.23M
Gross profit
$127.23M
Operating income
-$166.93M
Net income
-$207.6M
EBIT
-$169.98M
EBITDA
-$158.22M
Free cash flow
-$168.96M
Per share
Balance sheet
Liquidity
EPS
-$3.05
EPS diluted
-$3.05
Free cash flow per share
-$2.29
Book value per share
$9.08
Revenue per share
$1.73
TBVPS
$12.1
Total assets
$904.69M
Total liabilities
$264.82M
Debt
$222.2M
Equity
$639.87M
Working capital
$432.84M
Debt to equity
0.35
Current ratio
5.89
Quick ratio
5.74
Net debt/EBITDA
-1.15
Margins
Efficiency
Dividend
EBITDA margin
-124.4%
Gross margin
100%
Net margin
-163.2%
Operating margin
-131.2%
Return on assets
-22.5%
Return on equity
-32.2%
Return on invested capital
-16.6%
Return on capital employed
-20.8%
Return on sales
-133.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XNCR stock price
How has the Xencor stock price performed over time
Intraday
0%
1 week
3.01%
1 month
7.94%
1 year
-56.56%
YTD
-59.79%
QTD
17.56%
Financial performance
How have Xencor's revenue and profit performed over time
Revenue
$127.23M
Gross profit
$127.23M
Operating income
-$166.93M
Net income
-$207.6M
Gross margin
100%
Net margin
-163.2%
Xencor's net margin has shrunk by 92% YoY but it has increased by 22% QoQ
XNCR's operating margin has dropped by 78% year-on-year but it is up by 19% since the previous quarter
The company's net income fell by 42% YoY but it rose by 11% QoQ
Xencor's operating income has decreased by 32% YoY but it has increased by 6% from the previous quarter
Price vs fundamentals
How does XNCR's price correlate with its fundamentals
Growth
What is Xencor's growth rate over time
Valuation
What is Xencor stock price valuation
P/E
N/A
P/B
1.02
P/S
5.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.6
The EPS has decreased by 27% YoY but it has increased by 15% QoQ
XNCR's P/B is 61% below its 5-year quarterly average of 2.6 and 46% below its last 4 quarters average of 1.9
XNCR's equity is up by 7% year-on-year but it is down by 6% since the previous quarter
XNCR's P/S is 53% below its 5-year quarterly average of 11.4 and 45% below its last 4 quarters average of 9.8
XNCR's revenue is down by 26% year-on-year but it is up by 15% since the previous quarter
Efficiency
How efficient is Xencor business performance
The ROS has shrunk by 97% YoY but it has increased by 24% QoQ
XNCR's ROE is down by 44% YoY but it is up by 12% from the previous quarter
The ROA has contracted by 32% YoY but it has grown by 11% from the previous quarter
The ROIC has contracted by 27% YoY but it has grown by 12% from the previous quarter
Dividends
What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XNCR.
Financial health
How did Xencor financials performed over time
The company's current ratio fell by 27% YoY and by 11% QoQ
XNCR's quick ratio is down by 27% year-on-year and by 10% since the previous quarter
Xencor's debt is 65% lower than its equity
The debt to equity has decreased by 17% YoY but it has increased by 2.9% from the previous quarter
Xencor's debt has decreased by 13% YoY and by 4.2% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.